A validation promise needs an interim control strategy

What happened?

The 27 July 2026 letter describes a lack of cleaning validation for non-dedicated equipment. FDA found the response insufficient because interim plans and an assessment of distributed products were missing.

EDITORIAL INTERPRETATION

Why does it matter?

A future validation study does not, by itself, answer the separate question of how current and previously distributed batches are controlled.

Key points

• Define controls during remediation.
• Assess the scope of potentially affected products.
• Connect worst-case selection to equipment and process conditions.

Practical impact

Discussion prompt for QA: place the future study, interim controls and retrospective assessment on three separate lines in the action plan, each with an owner and evidence of completion.